Aurinia Pharmaceuticals (AUPH) shares were up more than 10% in recent trading Thursday after the company reported better-than-expected Q3 net income and revenue.
The company reported Q3 net income Thursday of $0.10 per diluted share, swinging from a net loss of $0.09 per share a year earlier.
Analysts polled by Capital IQ expected earnings of $0.02 per share.
Net revenue for the quarter ended Sept. 30 was $67.8 million, compared with $54.5 million a year earlier.
Analysts polled by Capital IQ expected $57.7 million.
The company said it will implement strategic restructuring, which includes reducing its workforce by about 45%, to focus on the commercial strategy for its Lupkynis treatment for lupus nephritis. This restructuring is estimated to yield over $40 million in annualized savings and $15 million to $19 million one-time charge in Q4.
Price: 8.33, Change: +0.81, Percent Change: +10.77
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。